Results 191 to 200 of about 665,294 (217)

The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis. [PDF]

Breast Care (Basel)
Berbari E, Anees A, Kaur R, Ayeni FE, Edirimanne S.   +4 more
europepmc   +1 more source

Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors. [PDF]

JNCI Cancer Spectr
Huang Y, Kwan ML, Heckbert SR, Smith NL, Othus M, Laurent CA, Roh JM, Rillamas-Sun E, Lee VS, Kolevska T, Cheng RK, Irribarren C, Nguyen-Huynh M, Hershman DL, Kushi LH, Greenlee H.   +15 more
europepmc   +1 more source

Effects of the efficacy of the <i>Yi Shen Tiao Gan</i> formula on aromatase inhibitor associated musculoskeletal syndrome: a randomized controlled trial. [PDF]

Front Pharmacol
Zhang Y, Chu M, Ye M, Cheng Y, Cong H, Yin Y, Chen H.   +6 more
europepmc   +1 more source

Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer. [PDF]

Front Oncol
Wang H, Zhang G, Gao W, Li S, Yang S, Zhang X, Wang J, Li C, Gao S, Geng C.   +9 more
europepmc   +1 more source

Correction to: "Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH".

J Clin Endocrinol Metab
europepmc   +1 more source

Reproductive changes in male rats treated perinatally with an aromatase inhibitor

Pharmacology Biochemistry and Behavior, 2002
The effects of maternal exposure to aromatase inhibitor during the perinatal period of sexual brain differentiation were studied. The fertility was assessed in adult, male rat offspring of aromatase inhibitor-treated dams.
Oduvaldo C M Pereira
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Fracture incidence after 3 years of aromatase inhibitor therapy

Annals of Oncology, 2014
Béatrice Bouvard, E Legrand, E Hoppe
exaly